Global leaders in consumer health, Haleon, and Brightseed, a pioneering AI-driven biosciences company, have announced a strategic collaboration to advance the discovery of plant-based small molecules that can enhance human health. This partnership will harness Brightseed’s Forager® AI platform to accelerate scientific insights into the natural world and support Haleon’s mission to develop innovative, science-led health solutions. Forager® is a state-of-the-art AI system designed to map bioactive compounds—substances in plants and other natural sources that affect human biology—and identify their mechanisms of action. Under the terms of this collaboration, Brightseed will make Forager® directly accessible to Haleon’s researchers, thereby integrating AI-powered discovery into their research and product development processes. “We are excited about this partnership, which significantly boosts our scientific capabilities and drives us toward groundbreaking advancements,” stated Sandrine Alvarado, VP and Head of Future Horizons R&D at Haleon. “Together, we aim to accelerate discoveries and innovations that are grounded in rigorous, trusted science and uphold the highest standards of scientific integrity.” Brightseed has already used its AI-driven approach to uncover important insights into plant compounds with potential benefits for metabolic health, gut health, immunity, and other areas. The partnership aligns perfectly with Haleon’s commitment to science-backed innovation and the development of next-generation natural health solutions. “With Forager’s AI, we can accelerate the pace of innovation and explore new avenues that were previously out of reach,” said Lee Chae, Co-Founder and CEO at Brightseed. “This collaboration positions Haleon to capitalize on these breakthroughs and transform them into a powerful engine for growth. By integrating Forager® into their research ecosystem, Haleon is furthering its mission to enhance everyday health through scientifically validated, nature-inspired solutions.” Haleon, listed on the London Stock Exchange (LSE: HLN) and the New York Stock Exchange (NYSE: HLN), is a leading name in consumer health, dedicated to delivering better everyday health with a focus on human values. The company’s product range covers five major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS). Haleon’s well-known brands, including Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum, are built on a foundation of trusted science, innovation, and deep human understanding. Brightseed, on the other hand, is an emerging force in the biosciences industry, specializing in the use of AI to uncover novel bioactive compounds from plants and natural sources. The company’s Forager® platform has demonstrated exceptional capabilities in mapping these compounds and their effects on human biology, facilitating the rapid discovery and commercialization of health solutions based on robust scientific evidence. The integration of Forager® with Haleon’s research efforts promises to unlock a wealth of new opportunities in the consumer health sector, enhancing the company’s ability to bring effective, nature-based products to market. Both organizations are committed to leveraging this partnership to achieve significant advances in health innovation, ultimately contributing to a healthier and more informed public. For more information, visit Haleon.com and Brightseedbio.com.